How a group of biotechs ran a covert campaign to push out the FDA commissioner

RegulatoryrejectedNegative

AI Analysis

Summary

Biohaven's spinocerebellar ataxia drug was previously rejected by the FDA. CEO Vlad Coric gained attention from FDA Commissioner Marty Makary in late April following this rejection.

Outcome Details

Spinocerebellar ataxia drug rejected by FDA

Importance:4/10

Sentiment:

-0.30

FDA rejectiondrug developmentregulatory affairscommissioner transition

Read the original article

Published by Endpoints News on May 21, 2026 6:26 PM

Read Original